(Q54423334)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Marie Wislez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Blaise Robin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jean-Luc Coll

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

6

Jacques Cadranel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Victor Jeannot

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Amandine Hurbin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Elisabeth Brambilla

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

13 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Cancer

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

2560-2571

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24374738%20AND%20SRC:MED&resulttype=core&format=json

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

3 March 2020

cites work

1 reference

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

The multiple roles of amphiregulin in human cancer.

21 January 2018

1 reference

Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells.

21 January 2018

1 reference

Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines

21 January 2018

1 reference

Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.

21 January 2018

1 reference

Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.

21 January 2018

1 reference

IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype

21 January 2018

1 reference

Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation

21 January 2018

1 reference

Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

21 January 2018

1 reference

Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines

21 January 2018

1 reference

Histone deacetylases and cancer.

21 January 2018

1 reference

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

21 January 2018

1 reference

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

21 January 2018

1 reference

HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma

21 January 2018

1 reference

Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.

21 January 2018

1 reference

The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase

21 January 2018

1 reference

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

21 January 2018

1 reference

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

Activation of AKT kinases in cancer: implications for therapeutic targeting

21 January 2018

1 reference

Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer

21 January 2018

1 reference

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

Mutations and response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

21 January 2018

1 reference

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

21 January 2018

1 reference

Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization

21 January 2018

1 reference

HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins

21 January 2018

1 reference

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

21 January 2018

1 reference

Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.

21 January 2018

1 reference

Mammalian sirtuins: biological insights and disease relevance

21 January 2018

1 reference

SIRT1 promotes DNA repair activity and deacetylation of Ku70

21 January 2018

1 reference

SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70

21 January 2018

1 reference

Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase

21 January 2018

1 reference

Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients

21 January 2018

1 reference

Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation

21 January 2018

1 reference

HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination

21 January 2018

1 reference

Histone deacetylase 10 promotes autophagy-mediated cell survival.

21 January 2018

1 reference

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

21 January 2018

1 reference

Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells

21 January 2018

1 reference

The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy

21 January 2018

1 reference

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

Pharmacodynamic markers of perifosine efficacy

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.

21 January 2018

1 reference

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference